An interventional study of Thoracoscopic surgery in Lung Cancer, Lung Cancer Metastatic and Bullous Disease Lung, sponsored by IRB of NTUH Hsin-Chu Branch. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-02-25.
Sponsored by IRB of NTUH Hsin-Chu Branch · Not applicable, Interventional, and Treatment
Among 195 studies in Lung Neoplasms with a site in Taiwan — 56 open to participants now, 77 under way, 19 of them phase 3. Lung Neoplasms · Taiwan.
Among the 195 studies in Lung Neoplasms with a site in Taiwan, this one is the 96th largest by enrollment of the 146 interventional ones, is one of 8 that started in 2018, is one of 37 with no phase, and was the 85th registered.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's enrollment of 110 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →56 of the 195 studies in Lung Neoplasms with a site in Taiwan are open now, in 12 countries. Each count lists the studies.
Of the 996 Lung Neoplasms studies recruiting now, 683 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 20 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →195 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2018.
Median enrollment 190 across the 146 interventional studies, 139 across the 49 observational. Of the 84 that completed or were terminated, 39 (46%) have results posted.
104 of 195 have an industry lead sponsor. The 10 most frequent:
IRB of NTUH Hsin-Chu Branch is the lead sponsor of 2 studies on the registry; none are open to participants now.
IRB of NTUH Hsin-Chu Branch has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Lung Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT05663242Kaohsiung Medical University Chung-Ho Memorial HospitalThe Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action | 2026-11-30 |
Among the 195 studies in Lung Neoplasms with a site in Taiwan, from their registry updates:
The investigators' study aims is to evaluate the safety and efficacy of uniportal VATS under assistance of needlescopic instruments through additional 2-3 mm ports compared to conventional uniportal VATS in patients with lung lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Lung or mediastinal disease requiring thoracoscopic surgery
Exclusion Criteria:
Thoracoscopic esophagectomy Decortication for empyema
Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
Procedure: Thoracoscopic surgery
Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
Procedure: Thoracoscopic surgery
Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
Pain scale POD 3
Post-operative day 3 pain scale documented using Visual Analogue Scale (VAS)
Time frame: 3 days
Pain scale POD 5
Post-operative day 5 pain scale documented using Visual Analogue Scale (VAS)
Time frame: 5 days
Hospital stay
Post-operative hospital stay
Time frame: 14 days
Post-operative 3 month neuralgia
Out patient documented using PainDETECT questionnaire (PD-Q)
Time frame: 3 months
Post-operative 6 month neuralgia
Out patient documented using PainDETECT questionnaire (PD-Q)
Time frame: 6 months
Cost
Total hospital cost
Time frame: 14 days
Surgical time
Time spend in surgery
Time frame: 1 day
Surgical bleeding
Blood loss during operation
Time frame: 1 day
Opioid using dosage
Total opioid equivalent dose used during post-operative course
Time frame: 14 days
Ran from Feb 2018 to primary completion in Dec 2018, 9 months.
Of 864 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's 9 months is below that.
Counting every sponsor, half of 915 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRB of NTUH Hsin-Chu Branch